Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection

Susan C. Fagan; David J. Edwards; Cesar V. Borlongan; Lin Xu; Ankur Arora; Giora Feuerstein; David C. Hess

doi:10.1016/j.expneurol.2003.12.006

Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection

Susan C. Fagan, David J. Edwards, Cesar V. Borlongan, Lin Xu, Ankur Arora, Giora Feuerstein, David C. Hess

Neurology

Research output: Contribution to journal › Article › peer-review

113 Scopus citations

Abstract

Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

Original language	English (US)
Pages (from-to)	248-251
Number of pages	4
Journal	Experimental Neurology
Volume	186
Issue number	2
DOIs	https://doi.org/10.1016/j.expneurol.2003.12.006
State	Published - Apr 2004

Keywords

Blood-brain barrier
Dose
Intraperitoneal
Minocycline
Neuroprotection
Pharmacokinetics

ASJC Scopus subject areas

Neurology
Developmental Neuroscience

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.expneurol.2003.12.006

Cite this

@article{737607783f5848a08572d89ea2aee32f,

title = "Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection",

abstract = "Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.",

keywords = "Blood-brain barrier, Dose, Intraperitoneal, Minocycline, Neuroprotection, Pharmacokinetics",

author = "Fagan, {Susan C.} and Edwards, {David J.} and Borlongan, {Cesar V.} and Lin Xu and Ankur Arora and Giora Feuerstein and Hess, {David C.}",

note = "Funding Information: This work was supported by grants from NINDS (1U01NS43127-01 and RO1NS044216-01) and the American Heart Association Southeast Affiliate (SCF, CVB), VA Merit Review (DCH), and VA Career Development Award (CVB).",

year = "2004",

month = apr,

doi = "10.1016/j.expneurol.2003.12.006",

language = "English (US)",

volume = "186",

pages = "248--251",

journal = "Experimental Neurology",

issn = "0014-4886",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Optimal delivery of minocycline to the brain

T2 - Implication for human studies of acute neuroprotection

AU - Fagan, Susan C.

AU - Edwards, David J.

AU - Borlongan, Cesar V.

AU - Xu, Lin

AU - Arora, Ankur

AU - Feuerstein, Giora

AU - Hess, David C.

N1 - Funding Information: This work was supported by grants from NINDS (1U01NS43127-01 and RO1NS044216-01) and the American Heart Association Southeast Affiliate (SCF, CVB), VA Merit Review (DCH), and VA Career Development Award (CVB).

PY - 2004/4

Y1 - 2004/4

N2 - Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

AB - Minocycline is currently under development as a neuroprotective agent in many different brain diseases. In more than a dozen experimental investigations in various models of brain injury, high doses of minocycline have been administered intraperitoneally. This report details new concerns with this route of administration and makes a case for intravenous dosing in experimental animals, particularly for acute neuroprotection, to optimize delivery to the brain and facilitate translation to human studies.

KW - Blood-brain barrier

KW - Dose

KW - Intraperitoneal

KW - Minocycline

KW - Neuroprotection

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=1542722933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542722933&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2003.12.006

DO - 10.1016/j.expneurol.2003.12.006

M3 - Article

C2 - 15026261

AN - SCOPUS:1542722933

SN - 0014-4886

VL - 186

SP - 248

EP - 251

JO - Experimental Neurology

JF - Experimental Neurology

IS - 2

ER -

Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this